[go: up one dir, main page]

EE200000022A - Uus ravimvorm - Google Patents

Uus ravimvorm

Info

Publication number
EE200000022A
EE200000022A EEP200000022A EEP200000022A EE200000022A EE 200000022 A EE200000022 A EE 200000022A EE P200000022 A EEP200000022 A EE P200000022A EE P200000022 A EEP200000022 A EE P200000022A EE 200000022 A EE200000022 A EE 200000022A
Authority
EE
Estonia
Prior art keywords
dosage form
new dosage
new
dosage
Prior art date
Application number
EEP200000022A
Other languages
English (en)
Inventor
Broadhead Joanne
Original Assignee
Astra Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharmaceuticals Limited filed Critical Astra Pharmaceuticals Limited
Publication of EE200000022A publication Critical patent/EE200000022A/et
Publication of EE04119B1 publication Critical patent/EE04119B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200000022A 1997-07-11 1998-06-29 Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod EE04119B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (2)

Publication Number Publication Date
EE200000022A true EE200000022A (et) 2000-10-16
EE04119B1 EE04119B1 (et) 2003-08-15

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000022A EE04119B1 (et) 1997-07-11 1998-06-29 Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod

Country Status (35)

Country Link
US (1) US6130208A (et)
EP (1) EP1000079B1 (et)
JP (1) JP4950380B2 (et)
KR (1) KR100786654B1 (et)
CN (2) CN1864696A (et)
AR (1) AR013157A1 (et)
AT (1) ATE340801T1 (et)
AU (1) AU8362598A (et)
BR (1) BR9810703A (et)
CA (1) CA2295628C (et)
CY (1) CY1105805T1 (et)
CZ (1) CZ298110B6 (et)
DE (1) DE69836023T2 (et)
DK (1) DK1000079T3 (et)
EE (1) EE04119B1 (et)
ES (1) ES2273425T3 (et)
HU (1) HU226489B1 (et)
ID (1) ID24716A (et)
IL (2) IL133868A0 (et)
IS (1) IS2439B (et)
MY (1) MY116421A (et)
NO (1) NO329918B1 (et)
NZ (1) NZ502073A (et)
PL (1) PL192768B1 (et)
PT (1) PT1000079E (et)
RU (1) RU2216330C2 (et)
SA (1) SA98190328B1 (et)
SE (1) SE9702680D0 (et)
SI (1) SI1000079T1 (et)
SK (1) SK285766B6 (et)
TR (1) TR200000006T2 (et)
TW (1) TW585764B (et)
UA (1) UA65576C2 (et)
WO (1) WO1999002542A1 (et)
ZA (1) ZA985669B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
HRP20200445T1 (hr) 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103338754A (zh) * 2010-12-10 2013-10-02 西格玛制药实验有限责任公司 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
EP2744424B1 (en) 2011-08-17 2017-11-08 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
CN115120606A (zh) 2013-03-09 2022-09-30 奇斯药制品公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MX391152B (es) 2015-01-14 2025-03-21 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (et) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
CN1864696A (zh) 2006-11-22
ES2273425T3 (es) 2007-05-01
SK285766B6 (sk) 2007-07-06
TR200000006T2 (tr) 2000-07-21
HU226489B1 (en) 2009-03-02
JP4950380B2 (ja) 2012-06-13
HK1026429A1 (en) 2000-12-15
CY1105805T1 (el) 2011-02-02
TW585764B (en) 2004-05-01
PL192768B1 (pl) 2006-12-29
AU8362598A (en) 1999-02-08
ID24716A (id) 2000-08-03
HUP0002622A3 (en) 2002-04-29
CA2295628C (en) 2008-07-29
DE69836023D1 (de) 2006-11-09
RU2216330C2 (ru) 2003-11-20
NO20000123L (no) 2000-03-03
DK1000079T3 (da) 2006-11-20
SI1000079T1 (sl) 2007-08-31
BR9810703A (pt) 2000-08-08
HUP0002622A2 (hu) 2001-05-28
JP2001509512A (ja) 2001-07-24
NO20000123D0 (no) 2000-01-10
KR20010021647A (ko) 2001-03-15
UA65576C2 (uk) 2004-04-15
NZ502073A (en) 2001-09-28
IL133868A0 (en) 2001-04-30
AR013157A1 (es) 2000-12-13
US6130208A (en) 2000-10-10
KR100786654B1 (ko) 2007-12-21
SE9702680D0 (sv) 1997-07-11
EP1000079A1 (en) 2000-05-17
PL337970A1 (en) 2000-09-11
SA98190328B1 (ar) 2006-08-15
IS2439B (is) 2008-11-15
IS5331A (is) 1999-12-30
DE69836023T2 (de) 2007-04-12
ZA985669B (en) 1999-01-11
WO1999002542A1 (en) 1999-01-21
IL133868A (en) 2010-05-17
EE04119B1 (et) 2003-08-15
ATE340801T1 (de) 2006-10-15
SK183699A3 (en) 2000-07-11
NO329918B1 (no) 2011-01-24
PT1000079E (pt) 2006-12-29
MY116421A (en) 2004-01-31
EP1000079B1 (en) 2006-09-27
CA2295628A1 (en) 1999-01-21
CZ298110B6 (cs) 2007-06-27
CZ200083A3 (cs) 2000-06-14
CN1263533A (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
EE200000192A (et) Uus kombinatsioon
NO20003640D0 (no) Ny doseringsform
ATE321483T1 (de) Dose
EE200000640A (et) Uus kasutamine
EE9900540A (et) Omeprasooli ravimvorm
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
DE69930866D1 (de) Dosiervorrichtung
DE69928777D1 (de) Dosierspender
IS5354A (is) Ný efnasambönd
IS5425A (is) Læknislyf
NO992692D0 (no) Nefadozon doseringsform
DE69918356D1 (de) Dosieraufsatz
NO980546D0 (no) Farmasöytiske midler
DE69919784D1 (de) Spritze
ID22228A (id) Turunan-turunan 16-hidroksi-11-(disubstitusifenil)-estra-4,9-diena
TR199802624A3 (tr) Yeni farmasötik.
EE200000022A (et) Uus ravimvorm
PT1036083E (pt) Novos 9a-azalidos
EE9900549A (et) Uus sool
DK0983266T3 (da) Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
DE69709326D1 (de) Dosiervorrichtung
EE9900455A (et) Uus menetlus
EE200100156A (et) Uus koostis
EE200100157A (et) Uus koostis
DE69710900D1 (de) Dosiervorrichtung

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231